Top Markets
Coin of the day
Fennec Pharmaceuticals Inc. Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

FENC
Rangering i aksjer #14209
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading... Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Aksjekurs
$12.33
Markedsverdi
$428.31M
Endring (1 dag)
0.49%
Endring (1 år)
39.01%
Land
US
Handel Fennec Pharmaceuticals Inc. (FENC)

Kategori

P/B-forhold for Fennec Pharmaceuticals Inc. (FENC)
P/B-forhold per 2026 TTM: 0
Ifølge Fennec Pharmaceuticals Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Fennec Pharmaceuticals Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH